Norgestrel, sold under the brand name Ovrette, was not discontinued for safety or effectiveness concerns. The manufacturer stopped distributing Ovrette in the United States on June 7, 2005, for commercial reasons. The FDA formally confirmed this in a 2017 Federal Register notice, stating that the drug was moved to its “Discontinued Drug Product List,” which specifically covers products removed from the market for reasons other than safety or effectiveness.
Why Ovrette Left the Market
Ovrette was a progestin-only birth control pill containing 0.075 mg of norgestrel. Its manufacturer, Wyeth (later acquired by Pfizer), chose to stop selling it. While the company never issued a detailed public explanation, the FDA’s own review concluded the withdrawal had nothing to do with the drug being unsafe or ineffective. Pharmaceutical companies routinely discontinue products for business reasons: low sales volume, manufacturing cost decisions, or strategic shifts in their product lines.
This distinction matters because when a drug is pulled for safety reasons, the FDA typically blocks generic versions from entering the market. By clarifying that Ovrette’s removal was purely a business decision, the FDA kept the door open for other companies to develop and sell norgestrel products.
What Made Norgestrel Less Popular
By the time Ovrette disappeared from pharmacy shelves, the contraceptive market had shifted considerably. Norgestrel belongs to an older generation of progestins with high androgenic activity, meaning it’s more likely to cause side effects like acne, unwanted hair growth, weight gain, fatigue, and depression compared to newer progestins. Many prescribers had already moved patients to formulations using less androgenic alternatives, which offered similar pregnancy prevention with a milder side effect profile.
The pill also had a notoriously strict dosing schedule. Missing a norgestrel pill by more than three hours requires backup contraception (like condoms) for two full days, according to CDC guidelines. Combined oral contraceptives and some newer progestin-only options offer wider windows for missed doses, making them more forgiving for real-world use. These factors likely contributed to declining prescriptions and, ultimately, the business case for discontinuation.
Norgestrel’s Return as Opill
The norgestrel story took a significant turn on July 13, 2023, when the FDA approved Opill, a 0.075 mg norgestrel tablet, as the first daily oral contraceptive available without a prescription in the United States. This was the same active ingredient and dose as the old Ovrette, now manufactured by Perrigo and sold over the counter.
With perfect use, norgestrel tablets prevent pregnancy about 98% of the time, meaning roughly 2 out of 100 women would become pregnant over a year. In typical real-world use, the effectiveness rate drops, largely because of the strict timing requirements. The FDA noted this gap between perfect and typical use but still determined the benefits of nonprescription access outweighed the risks.
The OTC approval was a landmark decision. For years after Ovrette’s discontinuation, norgestrel had essentially vanished from the U.S. market. Its reappearance in a form that doesn’t require a doctor’s visit made it the most accessible oral contraceptive in the country.
Other Norgestrel Products Still Available
Norgestrel also appears as an ingredient in certain combined oral contraceptives, where it’s paired with estrogen. Elinest, for example, combines ethinyl estradiol with norgestrel and remains available by prescription. These combination pills work differently from the progestin-only formulation. They suppress ovulation more reliably and have a more forgiving missed-dose window, though they carry the estrogen-related risks (blood clots, for instance) that progestin-only pills avoid.
For people specifically looking for the standalone norgestrel progestin-only pill that Ovrette once was, Opill is now the direct equivalent, with the added convenience of not needing a prescription.